Enhanced in vivo antileukemic efficacy of all-in-one CAR19–TIM-3–Fc T cells in a B-ALL PDX stress model. (A) Experimental design to compare CAR19 and all-in-one bicistronic CAR19–TIM-3–Fc T-cell efficacy and persistence in vivo under stress conditions (1.5 × 106 T cells comprising 0.175 × 106 CAR19+ or CAR19–TIM-3–Fc+ T cells; n = 5 mice per group). Leukemia engraftment and T-cell expansion were monitored weekly for 4 weeks. (B) Mouse weight during the follow-up. (C) Detection of TIM-3–Fc decoy in the plasma of animals treated with CAR19 or bicistronic CAR19–TIM-3–Fc T cells. (D) End point quantification of blasts in PB, spleen, and BM in the different groups of mice. (E) Total transduced (GFP+) T cells at end point in PB of animals treated with CAR19 or all-in-one CAR19–TIM-3–Fc T cells. All data are shown as mean ± standard error of the mean. ∗P ≤ .05; ∗∗∗P ≤ .001; not significant (ns); PB, peripheral blood; UT, untransduced.
